Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Diffuse Large B-Cell Lymphoma in Young Adults

Join Ahmet Dogan, MD, PhD and Andrew Zelenetz, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to diffuse large B-cell lymphoma (DLBCL) in Young Adults.

Diffuse large B‑cell lymphoma is the most common histologic subtype of non‑Hodgkin’s lymphoma (NHL) diagnosed in young adults (20-29 years).  Gene expression profiling (GEP) studies have shown that DLBCL is a heterogeneous group of distinct molecular subtypes with varied natural history and response to therapy. Germinal center B-cell (GCB) subtype and primary mediastinal B-cell lymphoma (PMBL) are the 2 molecular subtypes of DLBCL that are predominantly diagnosed in young adults. PMBL is more often diagnosed in young women. CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like chemotherapy regimens have been shown to be effective first-line treatment options for low-risk DLBCL in young adults. However, the optimal treatment of DLBCL in young adults remains unclear and the prognosis of DLBCL in this population continues to be inferior to that in children.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the molecular heterogeneity of DLBCL and its implications in the management of DLBCL in young adults
  • Identify the rationale for the development of novel therapeutic strategies and the mechanism of action of novel targeted therapies
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.86 ANCC contact hours
  • 0.75 Participation
Course opens: 
04/15/2016
Course expires: 
04/15/2017
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards (June 2015 - June 2016)

Ahmet Dogan, MD, PhD
Memorial Sloan Kettering Cancer Center

Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

 

Disclosure of Relevant Financial Relationships

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Faculty Disclosures
The faculty listed below have disclosed the following relevant financial relationships:

Ahmet Dogan, MD, PhD
Cancer Genetics Inc.: Scientific Advisor

Andrew D. Zelenetz, MD, PhD
Amgen Inc.: Consulting Fees, Honoraria
Axess Oncology: Consulting Fees, Honoraria
Bristol-Myers Squibb Company: Grant/Research Support
Celgene Corporation: Consulting Fees, Honoraria
Gilead Sciences, Inc.: Consulting Fees, Honoraria; Grant/Research Support
GlaxoSmithKline: Consulting Fees, Honoraria; Grant/Research Support
Hospira: Consulting Fees, Honoraria
Janssen Pharmaceutica Products, LP: Consulting Fees, Honoraria; Grant/Research Support
Medscape, LLC: Consulting Fees, Honoraria
Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fees, Honoraria
The France Foundation: Consulting Fees, Honoraria

NCCN Staff Disclosures

The activity planning staff listed below has no relevant financial relationships to disclose:

Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Kathy Smith, CMP, CHCP; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:

Mary Dwyer, MS; Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.86 contact hour. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-051-H01-P

Available Credit

  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.86 ANCC contact hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing